EUVIMEDEUVIMED entdecken
Open Access

Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study

Keiko Yanagihara, Masato Yoshida, Kensaku Awaji, Tamami Yamakawa, Sena Kato, Miki Tamura, Koji Nagata

Oncology Research · 2026

DOI: 10.32604/or.2025.073891 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Keiko Yanagihara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan. Hauptthemen laut MEDLINE: Piperazines, Breast Neoplasms, Pyridines, Antineoplastic Combined Chemotherapy Protocols. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesBreast NeoplasmsPyridinesAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, HormonalHumansFemaleRetrospective StudiesAgedErb-b2 Receptor Tyrosine KinasesMiddle AgedJapanReceptors, ProgesteroneReceptors, EstrogenAged, 80 and overAdultTreatment OutcomeProgression-Free SurvivalNeoplasm Metastasis

Stichwörter der Autor:innen

Metastatic breast cancercyclin-dependent kinase 4/6 (CDK4/6) inhibitorshormone receptor-positivehuman epidermal growth factor receptor 2-negative breast cancerreal-world evidence

Substanzen

palbociclibPiperazinesPyridinesErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenERBB2 protein, humanAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan.
  • Department of Pharmacy, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan.
  • Department of Pathology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo, 206-8512, Japan.

Zitieren

APA

Yanagihara, K., Yoshida, M., Awaji, K., Yamakawa, T., Kato, S., Tamura, M., & Nagata, K. (2026). Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study. Oncology Research. https://doi.org/10.32604/or.2025.073891

Vancouver

Yanagihara K, Yoshida M, Awaji K, Yamakawa T, Kato S, Tamura M, et al. Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study. Oncology Research. 2026. doi:10.32604/or.2025.073891

BibTeX
@article{Yanagihara2026,
  author = {Yanagihara, Keiko and Yoshida, Masato and Awaji, Kensaku and Yamakawa, Tamami and Kato, Sena and Tamura, Miki and Nagata, Koji},
  title = {Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2− Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study},
  journal = {Oncology Research},
  year = {2026},
  doi = {10.32604/or.2025.073891}
}
Kostenlos starten →